FDA Approves Bayer’s Sunharbo, the First Factor XIa Blood Thinner, Cutting Repeat Strokes 26% as a $748 Monthly Price Tests Demand
The FDA cleared Bayer’s Sunharbo (asundexian), the first Factor XIa inhibitor, after a 12,327-patient trial showed a 26% drop in repeat ischemic strokes without more major bleeding. Here is what the approval means for Bayer, its rivals and payers.
Read more